JP Morgan initiated coverage on Cidara Therapeutics with Overweight rating & tgt of $200, citing lead flu asset CD388’s game-changing potential.
Latest Ratings for CDTX
DateFirmActionFromTo Sep 2021Aegis CapitalMaintainsBuy Sep 2021WBB SecuritiesUpgradesBuyStrong Buy Mar 2021Aegis CapitalInitiates Coverage OnBuy